Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Chen JJ, Flanagan EP, Bhatti MT, et al. Neurology 2020; 95:e111-e120. Abstract Objective Myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) associated disorder (MOGAD) often manifests with recurrent CNS demyelinating attacks. The optimal treatment for reducing relapses is unknown. To help determine the efficacy of long-term immunotherapy in preventing relapse in […]
Which anti-MOG antibody treatment has the lowest relapse risk? — Neurochecklists Blog
from The Neurology Lounge https://ift.tt/36LjYIW
Comments
Post a Comment